BACKGROUND: A minority of patients with asthma have uncontrolled or partially controlled asthma despite intensive treatment. These patients present a special challenge because of the extensive diagnostic evaluation that they need, insufficient evidence regarding personalized treatments, and their high consumption of health-care resources. METHODS: The definition, diagnosis, and treatment of severe asthma are presented on the basis of a selective literature review and the authors' clinical experience. RESULTS: Severe asthma is present, by definition, when adequate control of asthma cannot be achieved by high-dose treatment with inhaled cortico - steroids and additional controllers (long-acting inhaled beta 2 agonists, montelukast, and/or theophylline) or by oral corticosteroid treatment (for at least six months per year), or is lost when the treatment is reduced. Before any further treatments are evaluated, differential diagnoses of asthma should be ruled out, comorbidities should be treated, persistent triggers should be eliminated, and patient adherence should be optimized. Moreover, pulmonary rehabilitation is recommended in order to stabilize asthma over the long term and reduce absences from school or work. The additional drugs that can be used include tiotropium, omalizumab (for IgE-mediated asthma), and azithromycin (for non-eosinophilic asthma). Antibodies against interleukin-5 or its receptor will probably be approved soon for the treatment of severe eosinophilic asthma. CONCLUSION: The diagnosis and treatment of severe asthma is time consuming and requires special experience. There is a need for competent treatment centers, continuing medical education, and research on the prevalence of severe asthma.
BACKGROUND: A minority of patients with asthma have uncontrolled or partially controlled asthma despite intensive treatment. These patients present a special challenge because of the extensive diagnostic evaluation that they need, insufficient evidence regarding personalized treatments, and their high consumption of health-care resources. METHODS: The definition, diagnosis, and treatment of severe asthma are presented on the basis of a selective literature review and the authors' clinical experience. RESULTS: Severe asthma is present, by definition, when adequate control of asthma cannot be achieved by high-dose treatment with inhaled cortico - steroids and additional controllers (long-acting inhaled beta 2 agonists, montelukast, and/or theophylline) or by oral corticosteroid treatment (for at least six months per year), or is lost when the treatment is reduced. Before any further treatments are evaluated, differential diagnoses of asthma should be ruled out, comorbidities should be treated, persistent triggers should be eliminated, and patient adherence should be optimized. Moreover, pulmonary rehabilitation is recommended in order to stabilize asthma over the long term and reduce absences from school or work. The additional drugs that can be used include tiotropium, omalizumab (for IgE-mediated asthma), and azithromycin (for non-eosinophilic asthma). Antibodies against interleukin-5 or its receptor will probably be approved soon for the treatment of severe eosinophilic asthma. CONCLUSION: The diagnosis and treatment of severe asthma is time consuming and requires special experience. There is a need for competent treatment centers, continuing medical education, and research on the prevalence of severe asthma.
Authors: Huib A M Kerstjens; Bernd Disse; Winfried Schröder-Babo; Theo A Bantje; Martina Gahlemann; Ralf Sigmund; Michael Engel; Jan A van Noord Journal: J Allergy Clin Immunol Date: 2011-06-02 Impact factor: 10.793
Authors: Marek L Kowalski; J S Makowska; M Blanca; S Bavbek; G Bochenek; J Bousquet; P Bousquet; G Celik; P Demoly; E R Gomes; E Niżankowska-Mogilnicka; A Romano; M Sanchez-Borges; M Sanz; M J Torres; A De Weck; A Szczeklik; K Brockow Journal: Allergy Date: 2011-02-14 Impact factor: 13.146
Authors: Raed A Dweik; Peter B Boggs; Serpil C Erzurum; Charles G Irvin; Margaret W Leigh; Jon O Lundberg; Anna-Carin Olin; Alan L Plummer; D Robin Taylor Journal: Am J Respir Crit Care Med Date: 2011-09-01 Impact factor: 21.405
Authors: William Busse; Roland Buhl; Carlos Fernandez Vidaurre; Martin Blogg; Jin Zhu; Mark D Eisner; Janice Canvin Journal: J Allergy Clin Immunol Date: 2012-02-23 Impact factor: 10.793
Authors: Teresa To; Sanja Stanojevic; Ginette Moores; Andrea S Gershon; Eric D Bateman; Alvaro A Cruz; Louis-Philippe Boulet Journal: BMC Public Health Date: 2012-03-19 Impact factor: 3.295
Authors: Jean Bousquet; Eva Mantzouranis; Alvaro A Cruz; Nadia Aït-Khaled; Carlos E Baena-Cagnani; Eugene R Bleecker; Chris E Brightling; Peter Burney; Andrew Bush; William W Busse; Thomas B Casale; Moira Chan-Yeung; Rongchang Chen; Badrul Chowdhury; Kian Fan Chung; Ronald Dahl; Jeffrey M Drazen; Leonardo M Fabbri; Stephen T Holgate; Francine Kauffmann; Tari Haahtela; Nikolaï Khaltaev; James P Kiley; Mohammad R Masjedi; Yousser Mohammad; Paul O'Byrne; Martyn R Partridge; Klaus F Rabe; Alkis Togias; Christiaan van Weel; Sally Wenzel; Nanshan Zhong; Torsten Zuberbier Journal: J Allergy Clin Immunol Date: 2010-11 Impact factor: 10.793
Authors: Antonius Schneider; Johannes Schwarzbach; Bernhard Faderl; Hubert Hautmann; Rudolf A Jörres Journal: Dtsch Arztebl Int Date: 2015-06-12 Impact factor: 5.594
Authors: Benedikt Kohler; Christina Kellerer; Konrad Schultz; Michael Wittmann; Oxana Atmann; Klaus Linde; Alexander Hapfelmeier; Antonius Schneider Journal: Dtsch Arztebl Int Date: 2020 Impact factor: 5.594
Authors: Ekaterina O Gubernatorova; Olga A Namakanova; Ekaterina A Gorshkova; Alexandra D Medvedovskaya; Sergei A Nedospasov; Marina S Drutskaya Journal: Front Immunol Date: 2021-05-18 Impact factor: 7.561